Futurology

In a recent InvestorIntel interview, Tracy Weslosky speaks with Greg Fenton, CEO and Director of ZEN Graphene Solutions Ltd. (TSXV: ZEN) about ZEN’s exclusive worldwide rights to commercialize rapid, saliva-based COVID-19 antigen testing technology announced yesterday In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Greg went on to say that this saliva-based test is exceptionally accurate, similar to current PCR tests, and will “revolutionize the way testing is done”. Affordable, easy to use, scalable and provides results in under 10 minutes, Greg comments that this technology has the ability “to allow economies to reopen.” Tracy then asks the critical question with “will you be able to test for anything?” About ZEN Graphene Solutions Ltd. ZEN is a next-gen nanomaterials technology company developing and commercializing technologies that help protect people and the environment. ZEN is currently focused on commercializing ZEN Guard